stockportfolio.pro
GMED vs TECH: Which Stock Is the Better Buy?
Globus Medical, Inc. and Bio-Techne Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — GMED vs TECH, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Globus Medical, Inc. (GMED) | Bio-Techne Corporation (TECH) | |
|---|---|---|
| Market cap | $11.0B | $11.0B |
| Revenue (latest FY) | $2.94B | $1.22B |
| Net income (latest FY) | $537.87M | $73.40M |
| Revenue growth (5y CAGR) | 30.1% | 10.5% |
| Net margin | 18.3% | 6.0% |
| Return on equity | 11.8% | 3.8% |
| P/E ratio | 18.9 | 101.2 |
| Dividend yield | — | 0.4% |
| Profitable years (of last 10) | 10 | 10 |
| Positive free cash flow | Yes | Yes |
See the full GMED vs TECH breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open GMED's full financials → Open TECH's full financials →More comparisons
Frequently asked questions
Which is bigger, GMED or TECH?
Bio-Techne Corporation is larger by market capitalization — $11.0B versus $11.0B.
Which grows faster, GMED or TECH?
Over the last five fiscal years, Globus Medical, Inc. grew revenue faster — 30.1%/yr versus 10.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
GMED fundamentals → · TECH fundamentals → · All 1,500+ companies → · Free screener →